ProCE Banner Activity

Frequently Asked Questions About BTK Inhibitor Use in B-Cell Malignancies

Clinical Thought
At our recent symposium at the 2019 ASH meeting, my colleagues and I discussed our perspectives on the use of BTK inhibitor therapy for B-cell malignancies. Here I have provided insights into to some of the major themes asked on this topic.

Released: February 21, 2020

Expiration: February 19, 2021

No longer available for credit.

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Loxo Oncology subsidiary of Eli Lilly

Faculty Disclosure

Primary Author

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that he has received consulting fees paid to his institution from AbbVie, Seattle Genetics, TG Therapeutics, and Verastem and funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead Sciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Merck, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Takeda, Teva, TG Therapeutics, Trillium, Unum, and Verastem.